Anticoagulant medication choices for cerebral venous thrombosis
Part of Brain & nervous system, Heart & circulation clinical trials.
This study looks at people with cerebral venous thrombosis who were treated with blood thinners taken by mouth (or started within the first 30 days). It uses observational data to understand how these treatments are used and what outcomes may follow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old when your cerebral venous thrombosis (CVT) was diagnosed
- Your CVT diagnosis was confirmed by imaging (CT-venography, MRI, or a catheter test)
- You started a mouth blood thinner within 30 days of diagnosis (or you can start with heparin first, then switch)
- You were included in the study within 90 days of your CVT diagnosis
- You agree to use your health data for the study (written consent for observational data)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking blood-thinning pills (called DOACs) after initial treatment can safely treat blood clots in the veins of the brain. You may be able to join if you recently had this condition and start the pills within the first two weeks of treatment.
This trial tests two blood thinner medicines, edoxaban and rivaroxaban, in Chinese patients with a blood clot in a brain vein (cerebral venous thrombosis). It aims to see if these medicines are safe and work well.
This trial tests a combination of blood thinners (anticoagulation) and a drug called tocilizumab, which targets inflammation, to treat acute cerebral venous thrombosis (a blood clot in a vein in the brain). It aims to see if this combined treatment improves recovery and reduces complications compared to blood thinners alone.
This trial tests whether adding a medication called batroxobin to standard blood thinners can help treat blood clots in the veins of the brain better than blood thinners alone. It is for people who have been diagnosed in the last month and are not at high risk for bleeding.
This study compares two blood thinners (dabigatran and rivaroxaban) to see which works better for treating a blood clot in the brain's veins. You may be eligible if you have a new diagnosis of this type of stroke and can start treatment within 14 days.
This study is for people who have been diagnosed with cerebral venous thrombosis (a blood clot in the brain’s venous system) at specific hospitals. It looks back at cases from 2014 to 2023 to learn from real-world patients.
Hear when a new Cerebral Venous Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.